Key result
Elevated cardiac troponin in cardiomyopathies is linked to poor prognosis and strong negative predictive value.
Why the study?
Does elevated cardiac troponin predict poor prognosis in patients with cardiomyopathies?
Does elevated cardiac troponin predict poor prognosis in patients with cardiomyopathies?
Answers are grounded in this paper and cite their sources.
Elevated cardiac troponin levels in patients with cardiomyopathies are consistently associated with poor prognosis, highlighting their potential utility in risk stratification.
Troponins are thin myofilament proteins that regulate the contraction of cardiac and skeletal muscle. The cardio-specific troponin I (TnI) and T (TnT) proteins are sensitive and specific biomarkers of myocardial injury which over the past twenty years have revolutionised the diagnosis and management of myocardial infarction. With the advent of high sensitivity assays the role for cardiac troponins is possibly expanding. Elevated levels are associated with adverse cardiovascular events and mortality in heart failure and the general population. Studies in cardiomyopathies are generally small with <200 patients, but serum troponin levels can be chronically raised and detect subclinical myocyte damage. This review examines all major published studies of cardiac troponin measurement in cardiomyopathies. There is considerable variability among studies regarding assays used and definitions of abnormal results but elevated troponin levels are almost invariably related to poor prognosis and their negative predictive value is important.
No takes yet. Share an insight, caveat, or question.
Connelly et al. (2016) conducted a review in Cardiomyopathies. Cardiac troponin measurement was evaluated on Prognosis. Elevated cardiac troponin levels in cardiomyopathies are consistently associated with poor prognosis and have an important negative predictive value.
Synapse has enriched 10 related papers. Consider them for comparative context: